The motion endorses a settlement in a lawsuit against major distributors of prescription opioids, aimed at addressing the opioid crisis in San Francisco. It also schedules a public hearing and a closed session for the Board of Supervisors to discuss the litigation with the City Attorney.
Motion calling from the Government Audit and Oversight Committee, pursuant to Board Rule 3.37, the proposed Ordinance (File No. 211072) endorsing settlement of the lawsuit filed on behalf of the City and County of San Francisco and the People of the State of California against large distributors of prescription opioids, entitled The City and County of San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc F/K/A Actavis Plc, Watson Pharmaceuticals, Inc. N/K/A Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. F/K/A/ Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; scheduling the Board of Supervisors to sit as a Committee of the Whole at the meeting on November 2, 2021, at 3:00 p.m. to hold a public hearing to consider the proposed Ordinance; and scheduling a closed session of the Board of Supervisors at the same meeting for the purpose of conferring with, or receiving advice from, the City Attorney regarding that existing litigation in which the City is a plaintiff, pursuant to California Government Code, Section 54956.9(a), and San Francisco Administrative Code, Section 67.10(d)(1).
How it got here
This legislation originated from a lawsuit settlement regarding opioid distributors, prompted by ongoing litigation initiated by the City against these companies.
The City filed a lawsuit against large distributors of prescription opioids, including Johnson & Johnson, alleging public nuisance and violations of competition laws due to deceptive marketing practices.
The Government Audit and Oversight Committee reviewed the proposed ordinance endorsing the settlement of the lawsuit, which was prepared for consideration by the Board of Supervisors.
The Board of Supervisors approved the motion calling for a public hearing and closed session regarding the proposed ordinance to endorse the settlement of the opioid lawsuit.
The Board of Supervisors scheduled to sit as a Committee of the Whole to hold a public hearing on the proposed ordinance endorsing the settlement of the lawsuit.
Reconstructed from attached documents & the official record
The ordinance authorizes a partial settlement of a lawsuit against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, for $6 million to $11 million over nine years due to their role in the opioid crisis. The lawsuit alleges that they created a public nuisance and violated laws through deceptive marketing and distribution of opioids in San Francisco.
The legislation involves a public hearing to discuss proposed ordinances related to a partial settlement of lawsuits against major opioid distributors and manufacturers, seeking abatement funds totaling between $33 million and $61 million over several years. This hearing is scheduled for November 2, 2021, at 3:00 p.m.
This legislation allows the San Francisco Board of Supervisors to hold a closed session to discuss legal advice regarding ongoing lawsuits against major opioid distributors and manufacturers, seeking settlement funds for the city. The lawsuits aim to secure between $27 million to $50 million and $6 million to $11 million in abatement funds to address the opioid crisis over specified timeframes.
The ordinance authorizes a partial settlement of a lawsuit against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, for $6 million to $11 million over nine years due to their role in the opioid crisis. The lawsuit alleges that they created a public nuisance and violated laws through deceptive marketing and distribution of opioids in San Francisco.
The legislation involves a public hearing to discuss proposed ordinances related to a partial settlement of lawsuits against major opioid distributors and manufacturers, seeking abatement funds totaling between $33 million and $61 million over several years. This hearing is scheduled for November 2, 2021, at 3:00 p.m.
This legislation allows the San Francisco Board of Supervisors to hold a closed session to discuss legal advice regarding ongoing lawsuits against major opioid distributors and manufacturers, seeking settlement funds for the city. The lawsuits aim to secure between $27 million to $50 million and $6 million to $11 million in abatement funds to address the opioid crisis over specified timeframes.
